Zura Bio Limited (NASDAQ:ZURA) Short Interest Up 27.7% in January

Zura Bio Limited (NASDAQ:ZURA) saw a large growth in short interest in the month of January. As of January 30th, there was short interest totaling 3,847,872 shares, a growth of 27.7% from the January 15th total of 3,012,119 shares. Approximately 7.6% of the company’s stock are short sold. Based on an average daily volume of 1,149,960 shares, the short-interest ratio is currently 3.3 days. Based on an average daily volume of 1,149,960 shares, the short-interest ratio is currently 3.3 days. Approximately 7.6% of the company’s stock are short sold.

Analyst Upgrades and Downgrades

ZURA has been the subject of several analyst reports. Leerink Partners raised shares of Zura Bio to a “strong-buy” rating in a research note on Sunday, November 23rd. Chardan Capital restated a “buy” rating and set a $10.00 target price on shares of Zura Bio in a report on Friday, November 14th. Wedbush began coverage on Zura Bio in a research report on Monday, February 9th. They issued an “outperform” rating and a $15.00 price target for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Zura Bio in a research note on Friday, January 9th. Finally, Wall Street Zen lowered Zura Bio from a “hold” rating to a “sell” rating in a report on Sunday, November 16th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $11.60.

Hedge Funds Weigh In On Zura Bio

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Allworth Financial LP bought a new stake in Zura Bio in the 4th quarter valued at $30,000. Scientech Research LLC acquired a new position in shares of Zura Bio during the third quarter valued at about $45,000. Forefront Wealth Partners LLC acquired a new position in shares of Zura Bio during the third quarter valued at about $93,000. Dimensional Fund Advisors LP bought a new stake in shares of Zura Bio in the fourth quarter valued at about $123,000. Finally, Squarepoint Ops LLC acquired a new stake in Zura Bio during the third quarter worth about $109,000. Institutional investors own 61.14% of the company’s stock.

Zura Bio Stock Performance

Shares of NASDAQ:ZURA opened at $6.08 on Monday. The stock’s 50-day moving average is $5.20 and its 200-day moving average is $3.73. The company has a market cap of $395.32 million, a P/E ratio of -9.35 and a beta of 0.21. Zura Bio has a 52-week low of $0.97 and a 52-week high of $6.88.

Zura Bio (NASDAQ:ZURA) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.02). As a group, equities analysts predict that Zura Bio will post -0.65 EPS for the current year.

About Zura Bio

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.